2010
DOI: 10.1128/jcm.02353-09
|View full text |Cite
|
Sign up to set email alerts
|

Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli

Abstract: Extended-spectrum-␤-lactamase (ESBL)-producing Escherichia coli (ESBLEC) is an increasing cause of community and nosocomial infections worldwide. However, there is scarce clinical information about nosocomial bloodstream infections (BSIs)caused by these pathogens. We performed a study to investigate the risk factors for and prognosis of nosocomial BSIs due to ESBLEC in 13 Spanish hospitals. Risk factors were assessed by using a case-control-control study; 96 cases (2 to 16% of all nosocomial BSIs due to E. col… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
110
1
9

Year Published

2012
2012
2021
2021

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 146 publications
(125 citation statements)
references
References 32 publications
(30 reference statements)
5
110
1
9
Order By: Relevance
“…In addition, antibiotic prescribers should be aware of the risk factors for infection with ESBL-producing E. coli isolates, including E. coli ST131, and should adapt their prescriptions accordingly (110,156,208,(211)(212)(213).…”
Section: Treatmentmentioning
confidence: 99%
“…In addition, antibiotic prescribers should be aware of the risk factors for infection with ESBL-producing E. coli isolates, including E. coli ST131, and should adapt their prescriptions accordingly (110,156,208,(211)(212)(213).…”
Section: Treatmentmentioning
confidence: 99%
“…The main risk factors for the development of MR bacterial infections in the general population are current or recent hospitalization, healthcare contact (i.e., hemodyalisis) and prior exposure to β-lactams or quinolones [33][34][35][36][37] . The same risk factors have been reported in cirrhosis.…”
Section: Infectionsmentioning
confidence: 99%
“…Collectively, our study characterizes a novel nonototoxic aminoglycoside and also introduces an approach to modifying existing aminoglycosides that can reduce ototoxicity while retaining antimicrobial activity. strains (9 of 10), including all 3 extended spectrum β lactamaseproducing (ESBL-producing) strains ( Figure 3A), which are multidrug resistant and known to be associated with high rates of patient mortality (35,36). N1MS inhibited 8 of 10 K. pneumoniae strains (including 3 of 5 ESBL producers), whereas sisomicin was active against 6 of 10 strains (1 of 5 ESBL producers; Figure 3B).…”
Section: Resultsmentioning
confidence: 99%